Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma

• Published in: JCO precision oncology Vol. 7; p. e2200543
• Main Authors: Chehrazi-Raffle, Alexander, Muddasani, Ramya, Dizman, Nazli, Hsu, JoAnn, Meza, Luis, Zengin, Zeynep B, Malhotra, Jasnoor, Chawla, Neal, Dorff, Tanya, Contente-Cuomo, Tania, Dinwiddie, Devin, McDonald, Bradon R, McDaniel, Timothy, Trent, Jeffrey M, Baehner, Frederick L, Murtaza, Muhammed, Pal, Sumanta K
• Format: Journal Article
• Language: English
• Published: United States 01.04.2023
• Subjects: Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Circulating Tumor DNA - genetics; Humans; Immunotherapy - methods; Kidney Neoplasms - drug therapy; Kidney Neoplasms - genetics; Kidney Neoplasms - pathology; Nivolumab - therapeutic use; Pilot Projects
• ISSN: 2473-4284
• DOI: 10.1200/PO.22.00543

Circulating tumor DNA (ctDNA) has been validated across multiple indications in the adjuvant and surveillance settings. We evaluated whether targeted digital sequencing (TARDIS) may distinguish a partial response (PR) from a complete response (CR) among patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitor (ICI) therapy. Eligible patients had mRCC that yielded a PR or CR to ICI therapy. Peripheral blood was obtained at a single time point for ctDNA analysis. TARDIS was used for quantification of average variant allele fractions (VAFs). Our primary objective was to determine the association between VAFs and depth of response (PR CR). A secondary objective was to determine whether VAFs were associated with disease progression. Twelve patients were analyzed, nine of whom achieved a PR (75%). Patients received either nivolumab monotherapy (50%) or nivolumab plus ipilimumab (50%). ctDNA analysis incorporated an average of 30 patient-specific mutations (range, 19-35); average coverage depth was 103,342 reads per target. TARDIS quantified a significant difference in VAFs between PR and CR (median, 0.181% [IQR, 0.077%-0.420%] 0.007% [IQR, 0.0%-0.028%], respectively [ = .014]). Of the 12 patients in the series, six patients demonstrated radiographic progression subsequent to ctDNA assessment. Patients who progressed on subsequent scans had significantly higher ctDNA than those who maintained their response (median, 0.362% [IQR, 0.181%-2.71%] 0.033% [IQR, 0.007%-0.077%], respectively [ = .026]). In this pilot study, TARDIS accurately differentiated PR from CR among patients with mRCC receiving immunotherapy, and also prospectively identified patients at risk for subsequent progression. Given these findings, we envision subsequent studies that validate these results and investigate the utility of this assay to discern appropriate candidates for discontinuation of immunotherapy.